GlassScriptPhysician profile
Amy M Barger
NPI 1295202992
$3,446.37
in general payments reported to CMS, 2019-2025
32 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $566 · 2022: $792 · 2023: $704 · 2024: $1,218 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $514.36 | 2021-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $327.55 | 2021-2024 | |
| Abbott Laboratories | $298.26 | 2022-2024 | Ensite Precision |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.73 | 2021-2024 | Jardiance |
| Pfizer INC. | $255.59 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $216.28 | 2021-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $208.22 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $155.07 | 2021-2024 | Farxiga |
| Esperion Therapeutics, INC. | $149.65 | 2021-2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $117.76 | 2024 | Inpefa |
| Amgen INC. | $114.48 | 2021-2024 | Repatha |
| Amarin Pharma, INC. | $99.81 | 2021-2022 | |
| Novo Nordisk INC | $96.33 | 2024-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $72.36 | 2021-2022 | |
| Scpharmaceuticals INC. | $60.93 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $57.58 | 2025 | Zepbound, Mounjaro |
| Medtronic, INC. | $54.89 | 2024 | Micra |
| Alnylam Pharmaceuticals INC. | $41.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $34.09 | 2021-2024 | Xarelto |
| Corcept Therapeutics | $31.78 | 2025 | Korlym |
| Philips North America LLC | $30.68 | 2023 | |
| Daiichi Sankyo INC. | $26.66 | 2023 | Injectafer |
| Edwards Lifesciences Corporation | $23.03 | 2022 | |
| Astellas Pharma US INC | $21.03 | 2021 | |
| Sumitomo Pharma America, INC. | $20.77 | 2024 | Orgovyx |
| Sanofi-Aventis U.S. LLC | $19.75 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $18.80 | 2024 | Opsumit |
| Lundbeck LLC | $18.48 | 2021 | |
| Baxter Healthcare | $18.30 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Cvrx, INC. | $16.28 | 2024 | Barostim Neo System |
| Currax Pharmaceuticals LLC | $14.88 | 2024 | Contrave |
| Arbor Pharmaceuticals, INC. | $14.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Barger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.